NTRA News and Press, Natera Inc. From 04/03/24

2024-04-03 15:44:21 ET More on Natera Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript Natera GAAP EPS of -$0.65 beats by $0.06, revenue of $311.1M beats by $23.78M Natera Q4 2023 Earn...

2024-04-01 08:42:12 ET Natera ( NASDAQ: NTRA ) and the Alliance for Clinical Trials in Oncology, part of the National Clinical Trials Network funded by the National Cancer Institute announced the launch of Alliance A032103, a randomized, phase II/III, biomarker-integrated trial. ...

First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms Approximately 1,000 patients will be enrolled at more than 300 sites Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical...

2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...

2024-03-22 15:27:11 ET Summary The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic company, focuses on women's health, oncology, and ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical tr...

2024-03-14 12:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Supports broader adoption of Natera’s Renasight TM test Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease , which was recently publ...

2024-03-13 14:01:40 ET More on Qiagen, Bio-Techne, etc. Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q4 2023 Earnings Call Transcript Bio-Techne Corporation (TECH) Q2 2024 Earnings Call Transcript Qiagen upgraded at Morgan Sta...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncolo...